Scientific Sessions 2025  /  Controversies in Lifetime Management of Aortic Stenosis Patients Under 65 years: TAVR vs SAVR First Strategy  /  Survival Is Key: Ross Operation
Logo

American Heart Association

  70
  0

Final ID:

Survival Is Key: Ross Operation

  • El-hamamsy, Ismail  ( Mount Sinai Hospital , New York , New York , United States )
  • Boskovski, Marko  ( UCSF , Boston , Massachusetts , United States )
  • Tseng, Elaine  ( UCSF and SFVA , South San Francisco , California , United States )
    • Author Disclosures:
    Ismail El-Hamamsy: DO NOT have relevant financial relationships | Marko Boskovski: DO have relevant financial relationships ; Consultant:Edwards Lifesciences:Active (exists now) | Elaine Tseng: DO have relevant financial relationships ; Research Funding (PI or named investigator):Amgen:Past (completed) ; Research Funding (PI or named investigator):Portrero Med:Past (completed) ; Research Funding (PI or named investigator):Cellphire:Past (completed)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Controversies in Lifetime Management of Aortic Stenosis Patients Under 65 years: TAVR vs SAVR First Strategy

Saturday, 11/08/2025 , 09:45AM - 11:00AM

Cardiovascular Seminar

More abstracts on this topic:
Case Presentation: Low-Risk Young (50-60 Years Old) Patient with Severe Symptomatic Aortic Stenosis

Hamilton Barbara, Scrimgeour Laura, Bromberger Bianca, Boskovski Marko

Is TAVR Increasing in the Young and What are the Outcomes?

Forcillo Jessica, Eltchaninoff Helene, Preventza Ourania, Ouzounian Maral

More abstracts from these authors:
Viewpoints: Ross Procedure Optimizes Life-Time Survival

El-hamamsy Ismail, Boskovski Marko, Bavaria Joseph, Fukuhara Shinichi

We have options: The surgical approach to the ACHD patient with Aortic Valve Disease

Starnes Vaughn, El-hamamsy Ismail

You have to be authorized to contact abstract author. Please, Login
Not Available